Catalog No.: PC-35732Not For Human Use, Lab Use Only.
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM.
PLB-1001 (Bozitinib, Vebreltinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM.
Similar with crizotinib, PLB-1001 inhibited the phosphorylation of MET and STAT3, indicating a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways.
PLB-1001 demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells (METex14) in preclinical models.
PLB-1001 also exhibits clinical potential for precisely treating gliomas.
